Expand AEMD Menu

About AEMD

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Aethlon Medical's lead therapeutic candidate is the Aethlon Hemopurifier, a device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. Aethlon Medical also provides government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis.
Primary Exchange: NASDAQ
SIC Laboratory Analytical Instruments
NAICS Analytical Laboratory Instrument Manufacturing

AEMD is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 26.2 B 2.62443E+10 3,660 3660 0.0% 0 1,071 1071